Ann Lab Med.  2020 Sep;40(5):409-413. 10.3343/alm.2020.40.5.409.

Prevalence and Immunophenotypic Characteristics of Monoclonal B-Cell Lymphocytosis in Healthy Korean Individuals With Lymphocytosis

• Yoo IY
• Bang SH
• Lim DJ
• Kim SJ
• Kim K
• Kim HJ
• Kim SH
• Cho D

• KMID: 2502571
• DOI: http://doi.org/10.3343/alm.2020.40.5.409

Abstract

Epidemiological studies of monoclonal B-cell lymphocytosis (MBL) have been conducted in limited geographical regions. Little is known about the prevalence of MBL in Asia. We investigated the prevalence and immunophenotypic characteristics of MBL in Koreans who had idiopathic lymphocytosis (lymphocyte count >4.0×109/L) and were ≥40 years of age. A total of 105 leftover peripheral blood samples met these criteria among those from 73,727 healthy individuals who visited the Health Promotion Center, Samsung Medical Center, Korea, from June 2018 to August 2019. The samples were analyzed using eight-color flow cytometry with the following monoclonal antibodies: CD45, CD5, CD10, CD19, CD20, CD23, and kappa and lambda light chains. The overall prevalence of MBL in the study population was 2.9% (3/105); there was one case of chronic lymphocytic leukemia (CLL)-like MBL (CD5+CD23+), one case of atypical CLL-like MBL (CD5+CD23−), and one case of CD5−MBL with a lambda restriction pattern. This is the first study on the MBL prevalence in an East Asian population, and it reveals a relatively low prevalence of MBL in healthy Korean individuals with lymphocytosis.

Keyword

Chronic lymphocytic leukemia; Monoclonal B-cell lymphocytosis; Prevalence; Immunophenotype; Korea

Reference

1. Landgren O, Albitar M, Ma W, Abbasi F, Hayes RB, Ghia P, et al. B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med. 2009; 360:659–67.

2. Shim YK, Middleton DC, Caporaso NE, Rachel JM, Landgren O, Abbasi F, et al. Prevalence of monoclonal B-cell lymphocytosis: a systematic review. Cytometry B Clin Cytom. 2010; 78(S1):S10–8.

3. Criado I, Rodríguez-Caballero A, Gutiérrez ML, Pedreira CE, Alcoceba M, Nieto W, et al. Low-count monoclonal B-cell lymphocytosis persists after seven years of follow up and is associated with a poorer outcome. Haematologica. 2018; 103:1198–208.

4. Marti GE, Rawstron AC, Ghia P, Hillmen P, Houlston RS, Kay N, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol. 2005; 130:325–32.

5. Nieto WG, Almeida J, Romero A, Teodosio C, López A, Henriques AF, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood. 2009; 114:33–7.

6. Shim YK, Rachel JM, Ghia P, Boren J, Abbasi F, Dagklis A, et al. Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding. Blood. 2014; 123:1319–26.

7. Rawstron AC, Ssemaganda A, de Tute R, Doughty C, Newton D, Vardi A, et al. Monoclonal B-cell lymphocytosis in a hospital-based UK population and a rural Ugandan population: a cross-sectional study. Lancet Haematol. 2017; 4:e334–40.

8. Aljurf M, Rawas F, Alnounou R, Bakshi N, Chaudhri N, Khalil S, et al. Prevalence and relative proportions of CLL and non-CLL monoclonal B-cell lymphocytosis phenotypes in the Middle Eastern population. Hematol Oncol Stem Cell Ther. 2017; 10:42–3.

9. Bajuk P, Furlan T, Podgornik H. Monoclonal B-cell lymphocytosis in the population of Slovenian region of Lower Carniola. Int J Lab Hematol. 2016; 38:341–6.

10. Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, et al. Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis. Haematologica. 2018; 103:e237–40.

11. Rossi D, Bruscaggin A, Spina V, Rasi S, Khiabanian H, Messina M, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011; 118:6904–8.

12. Schnaiter A, Paschka P, Rossi M, Zenz T, Bühler A, Winkler D, et al. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood. 2013; 122:1266–70.

13. Morabito F, Mosca L, Cutrona G, Agnelli L, Tuana G, Ferracin M, et al. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: a comparison of cellular, cytogenetic, molecular, and clinical features. Clin Cancer Res. 2013; 19:5890–900.

14. Lanasa MC, Allgood SD, Slager SL, Dave SS, Love C, Marti GE, et al. Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. Leukemia. 2011; 25:1459–66.

15. Jang MA, Yoo EH, Kim K, Kim WS, Jung CW, Kim SH, et al. Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior. Int J Hematol. 2013; 97:403–8.

16. Tomomatsu J, Isobe Y, Oshimi K, Tabe Y, Ishii K, Noguchi M, et al. Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior. Leuk Lymphoma. 2010; 51:2230–9.

17. Amato D, Oscier DG, Davis Z, Mould S, Zheng J, Kolomietz E, et al. Cytogenetic aberrations and immunoglobulin VH gene mutations in clinically benign CD5- monoclonal B-cell lymphocytosis. Am J Clin Pathol. 2007; 128:333–8.

18. Wang C, Amato D, Fernandes B. CD5-negative phenotype of monoclonal B-lymphocytosis of undetermined significance (MLUS). Am J Hematol. 2002; 69:147–9.

19. Parker E, Macdonald JR, Wang C. Molecular characterization of a t(2;7) translocation linking CDK6 to the IGK locus in CD5(−) monoclonal B-cell lymphocytosis. Cancer Genet. 2011; 204:260–4.